ASTANA – This year marks the fifth anniversary of the presence of Turkish pharmaceutical industry leader Abdi İbrahim on the Kazakh pharmaceutical market. Over these years, the company has been expanding its operations in Kazakhstan as well as constructing a modern pharmaceutical plant worth $30 million in Almaty region.
In 2012, Abdi Ibrahim bought a 60 percent share of Global Pharm, a leading Kazakh pharmaceutical producer.
The agreement envisaging the construction of the plant was signed in 2013 at the Turkish-Kazakh business forum in Istanbul. Kazakhstan President Nursultan Nazarbayev and then Turkish Prime Minister Recep Tayyip Erdoğan took part in the ceremony.
The facility with an annual production capacity of 24 million boxes and extensive portfolio of more than 100 varieties of pharmaceutical products now employs 200 people.
Increasing its presence in Kazakhstan allows the company to access the markets of the Commonwealth of Independent States countries and the Eurasian Economic Union members.
“Abdi Ibrahim managed to transfer its huge experience in pharmaceutical industry and advanced technologies in this field to AIGP, which produced a significant boost in the entire pharmaceutical market in Kazakhstan. At this moment, AIGP have several goals – further development of the industry, import substitution program and increasing export volumes,” said AIGP General Manager Ziyatkhan Gassanov.
AIGP is among 300 pharmaceutical companies in Kazakhstan that together generated 457 billion tenge (US$1.37 billion) in revenues in 2016, a two-fold increase from 274 billion (US$823.92 million) in 2013.
The Turkish producer launched a supply of pharmaceutical products from the Kazakh plant to Afghanistan, Azerbaijan and Georgia in April.
Apart from Kazakhstan and Turkey, the company also operates in seven countries – Albania, Algeria, Azerbaijan, Bosnia-Herzegovina, Georgia, Iraq, and Portugal.